Quotient has stressed the importance of screening prototype formulations early in the development process to ensure efficient drug delivery in later phases.
Speaking to Outsourcing-Pharma at this year’s AAPS conference in Washington, the firm’s VP, pharmaceutical sciences Peter Scholes explained the Rapid Fact program – a service Quotient offers to meet drug delivery challenges.
He told us that the main issues clients present are with soluability and half-life of the drug.
“The key challenge is a lack of in vivo, in vitro correlation,” said Scholes.
“It’s easy to develop the tablet in the lab to release over six or 12 hours, but the predictability of that in man is very difficult to asses.
“Quotient allow real-time flexibility because of our ability to make and dose on site.”